Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by McCoig, C. C.
Right arrow Articles by McCracken, G. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCoig, C. C.
Right arrow Articles by McCracken, G. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 43, 683-688
© 1999 The British Society for Antimicrobial Chemotherapy

Pharmacodynamics of trovafloxacin in experimental pneumococcal meningitis: basis for dosage selection in children with meningitis

Cynthia C. McCoig*, Loretta Wubbel, Hasan S. Jafri, Irja Lutsar, Rafael Bastero, Kurt Olsen, Sharon Shelton, Ian R. Friedland and George H. McCracken

Department of Pediatrics, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235-9063, USA

Trovafloxacin is a recently approved fluoroquinolone with excellent activity against Gram- positive and Gram-negative organisms that offers a potential alternative for treatment of ß-lactam-resistant pneumococcal meningitis. Using the rabbit meningitis model, we sought to characterize the pharmacodynamic properties of trovafloxacin in the cerebrospinal fluid (CSF). Animals were given single doses of trovafloxacin of 10, 15, 20 or 30 mg/kg; 1 h after infusion mean CSF concentrations were 0.59 ± 0.18, 0.74 ± 0.14, 1.12 ± 0.12 and 1.07 ± 0.35 mg/L, respectively. The bacterial killing rate increased with increasing dosages of trovafloxacin, indicating that its activity is concentration dependent. All three pharmacodynamic indices (area under the concentration curve (AUC)/MBC, peak concentration (C max)/MBC, and time above MBC (T > MBC)) correlated with bacterial killing; however, AUC/MBC correlated best (r = 0.71). In a second experiment we found comparable bacterial killing with multiple doses of trovafloxacin given either every serum half-life or every two serum half-lives. In both experiments bacterial regrowth occurred when the concentration of trovafloxacin in CSF fell below the MBC. These data have been used in formulating an appropriate regimen for trovafloxacin treatment of bacterial meningitis in children.

* Corresponding author. Tel: +1-214-648-3720; Fax: +1-214-648-2961.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
V. Rodriguez-Cerrato, F. Ghaffar, J. Saavedra, I. C. Michelow, R. D. Hardy, J. Iglehart, K. Olsen, and G. H. McCracken Jr.
BMS-284756 in Experimental Cephalosporin-Resistant Pneumococcal Meningitis
Antimicrob. Agents Chemother., November 1, 2001; 45(11): 3098 - 3103.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. D. Cubbon and R. G. Masterton
New quinolones--a fresh answer to the pneumococcus
J. Antimicrob. Chemother., December 1, 2000; 46(6): 869 - 872.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.